ROCHE SORIATANE HALF-LIFE IS SHORTER THAN TEGISON; PSORIASIS DRUG LAUDED BY PSORIASIS FOUNDATION AS IMPROVEMENT FOR WOMEN OF CHILD BEARING AGE
Executive Summary
The shorter half-life of Roche's systemic retinoid Soriatane (acitretin) compared to the company's Tegison (etretinate) may make it an alternative for women of child bearing age with severe, unresponsive psoriasis. FDA approved the drug Oct. 28.